ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,542,527 | -13.3% | 598,403 | -0.0% | 0.02% | -15.0% |
| Q2 2023 | $14,461,644 | +31.1% | 598,578 | +3.0% | 0.02% | +25.0% |
| Q1 2023 | $11,027,527 | +13.0% | 581,314 | -5.4% | 0.02% | +6.7% |
| Q4 2022 | $9,758,054 | -4.5% | 614,487 | -1.8% | 0.02% | -11.8% |
| Q3 2022 | $10,222,000 | +15.0% | 625,564 | -0.7% | 0.02% | +30.8% |
| Q2 2022 | $8,890,000 | -40.8% | 630,080 | +1.7% | 0.01% | -31.6% |
| Q1 2022 | $15,011,000 | +5.6% | 619,525 | +1.4% | 0.02% | +11.8% |
| Q4 2021 | $14,212,000 | +38.5% | 610,759 | -0.8% | 0.02% | +30.8% |
| Q3 2021 | $10,263,000 | -8.5% | 615,631 | +33.9% | 0.01% | -13.3% |
| Q2 2021 | $11,215,000 | +2703.8% | 459,812 | +2947.1% | 0.02% | +1400.0% |
| Q1 2021 | $400,000 | +1381.5% | 15,090 | +1409.0% | 0.00% | – |
| Q1 2019 | $27,000 | -15.6% | 1,000 | -50.0% | 0.00% | – |
| Q4 2018 | $32,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |